Latest Lead News

I Synergy Group Limited has reshaped its board with the resignation of Joshua Hunt, the appointment of Jiayi Yu as Non-Executive Director, and the promotion of Heng Jee Meng to Managing Director, signaling a renewed focus on shareholder value.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Peako Limited reports compelling exploration results from its East Kimberley projects alongside the granting of new lithium-focused tenements and a successful $1.8 million capital raise.

Brazilian Critical Minerals Ltd reports breakthrough test results from its Ema ionic clay rare earth project, producing a high-purity mixed rare earth carbonate and advancing drilling, logistics, and environmental assessments.

Sipa Resources has acquired Buru Energy's 50% stake in the Barbwire Terrace Project, gaining 100% ownership and full operational control. The deal includes a 0.6% Net Smelter Return royalty, positioning Sipa to advance exploration of promising zinc-lead-silver targets in Western Australia.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Connected Minerals Ltd has successfully raised $5.1 million to fuel its aggressive uranium exploration in Namibia, reporting impressive high-grade rock chip results that set the stage for maiden drilling in early 2025.

Stavely Minerals has reported significant progress in its copper and nickel exploration projects, highlighting promising assay results and new structural insights that could unlock major resource expansions.

Falcon Metals reports steady progress across its Victorian and Western Australian projects, maintaining a strong cash position to fuel ongoing exploration in 2025.

Godolphin Resources reports significant drilling success at Lewis Ponds with thick massive sulphide intersections and advances its Narraburra Rare Earths project with high-value carbonate samples, supported by a strong capital raise.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.